{"title":"블로터 ─ 비즈니스 ─ 헤드라인","url":"https://www.bloter.net/section?id=sectionBusiness2","favicon":"https://www.bloter.net/favicon.png","elements":[{"title":"GC셀, 美 바이오센트릭 인수…3.5% CDMO 매출 비중 얼마나 늘까?","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\">2022-04-21 10:54:10</span>","link":"https://www.bloter.net/newsView/blt202204210005","retrieved":1650511776433,"image":"https://www.bloter.net/data/blt/image/2022/04/21/blt202204210005.570x320.0.png"},{"title":"SK바사 독감 백신 생산 계획이 GC녹십자에 미치는 영향","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202203150377","retrieved":1650511776434},{"title":"삼바·셀트·SK바사, 엔데믹 전환에 ‘새 판짜기’…재무적 여력은?","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202203030153","retrieved":1650511776435},{"title":"대웅제약, 개발비 자산화율 상승세…탄탄한 R&D로 실적도 ‘방긋’","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202202160205","retrieved":1650511776442},{"title":"코로나19 ‘엔데믹’ 전환 신호…‘백신 올인’ SK바사, 다음은 있을까","contents":"<span class=\"writer\">정두용</span>                        <span class=\"date\"></span>","link":"https://www.bloter.net/newsView/blt202202130003","retrieved":1650511776443}]}